ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,306,319,218 | -10.4% | 48,132,615 | +1.5% | 0.13% | -7.6% |
Q2 2023 | $1,457,994,028 | -14.5% | 47,429,861 | +0.2% | 0.14% | -21.3% |
Q1 2023 | $1,706,037,085 | -12.3% | 47,350,458 | -3.8% | 0.18% | -17.2% |
Q4 2022 | $1,946,203,263 | -3.5% | 49,246,032 | -1.9% | 0.22% | -19.6% |
Q3 2022 | $2,016,482,000 | -6.9% | 50,186,161 | -2.6% | 0.28% | -2.1% |
Q2 2022 | $2,166,876,000 | +3.9% | 51,543,171 | -3.7% | 0.28% | 0.0% |
Q1 2022 | $2,085,987,000 | -6.9% | 53,541,788 | -4.8% | 0.28% | +1.4% |
Q4 2021 | $2,240,794,000 | +8.2% | 56,230,690 | -1.9% | 0.28% | -0.7% |
Q3 2021 | $2,071,013,000 | -0.5% | 57,305,311 | +12.8% | 0.28% | +1.5% |
Q2 2021 | $2,082,049,000 | -0.8% | 50,794,041 | +5.6% | 0.28% | -10.7% |
Q1 2021 | $2,098,917,000 | +76.2% | 48,118,242 | +102.2% | 0.31% | +67.4% |
Q4 2020 | $1,191,094,000 | +202.3% | 23,798,081 | +154.1% | 0.18% | +142.1% |
Q3 2020 | $394,053,000 | +30.8% | 9,366,618 | +50.9% | 0.08% | +13.4% |
Q2 2020 | $301,261,000 | – | 6,205,186 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
Brown University | 381,759 | $16,652,000 | 11.44% |
Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |